Literature DB >> 3488537

Hypercalciuria, hyperphosphaturia, and growth retardation in children with diabetes mellitus.

J I Malone, S Lowitt, J A Duncan, S C Shah, A Vargas, A W Root.   

Abstract

The role of hypercalciuria and hyperphosphaturia in the growth retardation of children with diabetes mellitus was investigated in 157 children with diabetes whose mean height was less than that of 37 nondiabetic siblings of similar age (P less than .025). Hyperglycemia, hypercalciuria, and hyperphosphaturia were assessed coincident with the height measurement of each child in a cross-sectional survey. The distribution of height percentiles of the children with diabetes was skewed to the left with 61% at or below the 50th percentile. Eleven percent of the insulin-dependent children with diabetes mellitus were shorter than would be anticipated by a normal distribution of the 157 children. The duration of diabetes (hyperglycemia) had the greatest influence upon the children's height. Children with diabetes were shorter than the nondiabetic subjects by the fourth year of hyperglycemia, and this difference in height became statistically significant after 7 years or more of diabetes. The degree of hypercalciuria and hyperphosphaturia was more closely associated with reduced height in children with diabetes than was the degree of hyperglycemia, although the renal wastage of calcium and phosphorus seemed to be the result of glucosuria. Because hypercalciuria and hyperphosphaturia impair growth in nondiabetic children, they may also play an important role in the poor growth of children with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488537

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

Review 1.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

Review 2.  Epidemiology of Skeletal Health in Type 1 Diabetes.

Authors:  David R Weber; George Schwartz
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

3.  Urinary mineral excretion in healthy Iranian children.

Authors:  Mohammad R Safarinejad
Journal:  Pediatr Nephrol       Date:  2002-12-21       Impact factor: 3.714

4.  Proteomic identification and immunolocalization of increased renal calbindin-D28k expression in OVE26 diabetic mice.

Authors:  Visith Thongboonkerd; Shirong Zheng; Kenneth R McLeish; Paul N Epstein; Jon B Klein
Journal:  Rev Diabet Stud       Date:  2005-05-10

5.  SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.

Authors:  Kathryn M Thrailkill; R Clay Bunn; Jeffry S Nyman; Mallikarjuna R Rettiganti; Gael E Cockrell; Elizabeth C Wahl; Sasidhar Uppuganti; Charles K Lumpkin; John L Fowlkes
Journal:  Bone       Date:  2015-07-23       Impact factor: 4.398

6.  Reversible reduction in bone blood flow in streptozotocin-diabetic rats.

Authors:  P D Lucas
Journal:  Experientia       Date:  1987-08-15

7.  Calcitonin secretion in children with insulin-dependent diabetes mellitus.

Authors:  G Saggese; S Bertelloni; G I Baroncelli; P Ghirri
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183

8.  Does glycemic control affect growth velocity in children with insulin-dependent diabetes mellitus.

Authors:  P Pitukcheewanont; R Alemzadeh; W R Jacobs; B H Jones; A J Eberle
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

9.  Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.

Authors:  Kathryn M Thrailkill; R Clay Bunn; Sasidhar Uppuganti; Philip Ray; Iuliana Popescu; Evangelia Kalaitzoglou; John L Fowlkes; Jeffry S Nyman
Journal:  Bone       Date:  2020-09-02       Impact factor: 4.398

10.  Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone.

Authors:  Kathryn M Thrailkill; R Clay Bunn; Sasidhar Uppuganti; Philip Ray; Kate Garrett; Iuliana Popescu; Jacquelyn S Pennings; John L Fowlkes; Jeffry S Nyman
Journal:  Bone       Date:  2020-01-25       Impact factor: 4.398

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.